By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Oncothyreon Inc. 

2601 Fourth Avenue
Suite 500
Seattle  Washington  98121   U.S.A.
Phone: 206-801-2100 Fax: 206-801-2101


SEARCH JOBS


Industry
Biotechnology






Company News
Oncothyreon (ONTY) Highlights Novel Checkpoint Kinase 1 Inhibitors At AACR Annual Meeting 2016 4/19/2016 8:00:21 AM
Oncothyreon (ONTY) Names a New CEO 3/29/2016 8:10:49 AM
Oncothyreon Inc. (ONTY) Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update 3/15/2016 8:27:38 AM
Oncothyreon Inc. (ONTY) Announces First Patient Dosed In Randomized Phase II ONT-380 Combination Trial In Patients With HER2-Positive Breast Cancer 2/29/2016 7:44:12 AM
Oncothyreon Inc. (ONTY) Appoints Christopher Henney, Ph.D., D.Sc. As Interim CEO And Expands Board With Additions Of Mark Lampert And Gwen Fyfe, M.D. 1/11/2016 8:16:46 AM
Oncothyreon Inc. (ONTY) Announces Data For ONT-380 In HER2-Positive Breast Cancer Patients With And Without Brain Metastases At The San Antonio Breast Cancer Symposium 12/9/2015 7:31:46 AM
Oncothyreon Inc. (ONTY) Announces Webcast To Review Updated Clinical Data On ONT-380 In HER2-Positive Breast Cancer Patients 12/2/2015 8:00:22 AM
Oncothyreon Inc. (ONTY) To Present Updated Data On ONT-380 For The Treatment Of HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium 11/16/2015 8:19:39 AM
Oncothyreon Inc. (ONTY) To Present At Rodman & Renshaw Annual Global Investment Conference 9/2/2015 7:46:00 AM
Oncothyreon Inc. (ONTY) Reports Second Quarter 2015 Financial Results 8/7/2015 8:23:08 AM
12345678910...
//-->